Related Experiment Videos
Extrapulmonary pneumocystosis: clinical features in human immunodeficiency virus infection
D W Northfelt1, M J Clement, S Safrin
1Division of AIDS Activities, University of California, San Francisco.
Abstract:
Pneumocystis carinii infection is reported with increasing frequency as a cause of disease outside of the respiratory tract in patients with human immunodeficiency virus (HIV) infection. Extrapulmonary pneumocystosis is not limited to patients in any discrete risk group for HIV infection. Patients with HIV infection who develop extrapulmonary pneumocystosis frequently do not have concurrent P. carinii pneumonia. Signs and symptoms of extrapulmonary pneumocystosis are nonspecific but when present are frequently referable to the tissues or organs involved. Extrapulmonary pneumocystosis can be diagnosed by examination of tissue biopsies from affected sites using standard histologic techniques. Therapy with antimicrobial agents used to treat P. carinii pneumonia has been effective in some patients. An association between use of aerosolized pentamidine for prevention of P. carinii pneumonia and development of extrapulmonary pneumocystosis has been suggested but remains unconfirmed. Other factors such as the use of zidovudine and duration of immunodeficiency may also be important to the pathogenesis of extrapulmonary pneumocystosis. Further studies are needed to better identify risk factors that may predispose patients to the development of extrapulmonary pneumocystosis.
Insights
Extrapulmonary Pneumocystis pneumonia (PCP) is increasingly seen in HIV patients, often without lung involvement. Early diagnosis via biopsy and prompt treatment are key for managing this opportunistic infection.
Area of Science:
- Infectious Diseases
- Immunology
- Medical Microbiology
Background:
- Pneumocystis carinii pneumonia (PCP) is a significant opportunistic infection in human immunodeficiency virus (HIV)-infected individuals.
- The increasing frequency of extrapulmonary disease necessitates a better understanding of its epidemiology and risk factors.
Observation:
- Extrapulmonary pneumocystosis occurs in HIV patients across various risk groups and often presents without concurrent pulmonary infection.
- Clinical manifestations are nonspecific and depend on the affected organ system.
- Diagnosis relies on histopathological examination of tissue biopsies from affected sites.
Findings:
- Extrapulmonary pneumocystosis is a growing concern in the HIV population.
- The condition is not confined to specific HIV risk groups.
- Patients may have extrapulmonary disease without evidence of pneumonia.
Implications:
- Early recognition and diagnosis of extrapulmonary pneumocystosis are crucial for effective management in HIV patients.
- Further research is needed to elucidate the specific risk factors, including the role of antiretroviral therapy and duration of immunodeficiency.
- Understanding the pathogenesis may lead to improved preventative strategies and treatment protocols for this severe complication.